Pieris Pharmaceuticals Inc logo

Pieris Pharmaceuticals Inc

$ 1.13 -0.0214 (-1.86%) 11:08 AM EST
P/E:
At Loss
P/B:
1.88
Market Cap:
$ 83.33M
Enterprise V:
$ 17.87M
Volume:
24.79K
Avg Vol (2M):
192.12K
Also Trade In:
Volume:
24.79K
Market Cap $:
83.33M
PE Ratio:
At Loss
Avg Vol (2-Month):
192.12K
Enterprise Value $:
17.87M
PB Ratio:
1.88
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 6.11
Equity-to-Asset 0.39
Debt-to-Equity 0.3
Debt-to-EBITDA -0.33
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.98
Distress
Grey
Safe
Beneish M-Score -2.11
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.62
9-Day RSI 28.07
14-Day RSI 30.09
6-1 Month Momentum % -51.82
12-1 Month Momentum % -71.76

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.56
Quick Ratio 2.56
Cash Ratio 2.28
Days Sales Outstanding 42.08

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.1

Financials (Next Earnings Date:2022-11-02 Est.)

PIRS's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:PIRS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 27.186
EPS (TTM) ($) -0.58
Beta 1.12
Volatility % 48.71
14-Day RSI 30.09
14-Day ATR ($) 0.082129
20-Day SMA ($) 1.318
12-1 Month Momentum % -71.76
52-Week Range ($) 1.1 - 5.295
Shares Outstanding (Mil) 74.41

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Pieris Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Pieris Pharmaceuticals Inc Analysis

Share your research

Headlines

See More
No news.